Canakinumab shows promising efficacy and tolerability in children with systemic JIA
The study found that canakinumab significantly improved symptoms of systemic juvenile idiopathic arthritis (sJIA) in children, achieving an ACR Pedi 50 score within 15 days. Steroid tapering was also observed in the majority of responders, and 'inactive' disease status was reached in 4 cases.